What is the recommended moxifloxacin dose for an adult patient with end‑stage renal disease on dialysis?

Moxifloxacin Dosing in CKD5D (End-Stage Renal Disease on Dialysis)

Administer moxifloxacin 400 mg once daily without dose adjustment in patients with end-stage renal disease on dialysis. 1

Dosing Recommendation

• Standard dose: 400 mg once daily (oral or intravenous), regardless of dialysis status 1
• No frequency change required – unlike other fluoroquinolones (e.g., levofloxacin requires dose reduction to 750-1000 mg three times weekly), moxifloxacin maintains daily dosing 1
• Timing: Administer after hemodialysis on dialysis days to facilitate directly observed therapy and avoid premature drug removal 1

Pharmacokinetic Rationale

The standard dosing is supported by moxifloxacin's unique pharmacokinetic profile in renal failure:

• Minimal renal clearance: Only ~20% of moxifloxacin is excreted unchanged in urine, with the majority eliminated via hepatic metabolism (52% as glucuronide and sulfate conjugates) 2
• Dialysis removal is negligible: Hemodialysis removes only ~9% of moxifloxacin, and CAPD removes only ~3% 2
• AUC remains unchanged: In patients with severe renal impairment (CrCl <30 mL/min) and those on hemodialysis, systemic exposure (AUC) is comparable to healthy volunteers 2, 3, 4
• Cmax slightly reduced: Peak concentrations may be 22-45% lower in dialysis patients, but this does not compromise efficacy 2

This contrasts sharply with levofloxacin, which undergoes greater renal clearance and requires dose adjustment to three-times-weekly dosing in dialysis patients 1

Important Caveats

Metabolite Accumulation

• Glucuronide conjugate (M2) accumulates significantly in renal failure, with AUC increasing 7.5-fold in dialysis patients 2, 5
• Sulfate conjugate (M1) increases 1.4-1.5-fold in dialysis patients 2, 5
• Clinical significance unknown: These metabolites are not microbiologically active, and no adverse outcomes have been attributed to their accumulation 2
• Monitor for QT prolongation: Given metabolite accumulation and the known risk of QT prolongation with fluoroquinolones, ECG monitoring may be prudent in high-risk patients 2

Pharmacodynamic Considerations

• MIC/PK targets are met: Studies confirm that Cmax/MIC90 and AUC0-24/MIC90 ratios exceed thresholds for clinical success against common pathogens in dialysis patients 4, 6
• For pathogens with MIC90 >0.5 mg/L: Standard dosing may be insufficient, and higher doses or alternative agents should be considered 6

Peritoneal Dialysis

• Use hemodialysis dosing recommendations as a starting point for CAPD patients 1
• Peritoneal penetration is excellent: Peritoneal fluid-to-plasma ratios range 0.84-1.00, making moxifloxacin effective for CAPD-related peritonitis 4
• Verify adequacy with therapeutic drug monitoring when available, as specific data for peritoneal dialysis are limited 1

Monitoring Recommendations

• Serum drug concentration monitoring should be considered in complex cases to ensure adequate absorption without excessive accumulation 1
• Watch for drug interactions: ESRD patients often take multiple medications that may interact with moxifloxacin or affect its absorption 1
• Assess for comorbidities: Conditions like diabetic gastroparesis may impair drug absorption 1

Practical Algorithm

1. Confirm indication for moxifloxacin (e.g., community-acquired pneumonia, skin/soft tissue infection, tuberculosis) 1
2. Prescribe 400 mg once daily (no adjustment needed) 1, 2
3. Schedule administration after dialysis on dialysis days 1
4. Separate from multivalent cations (give moxifloxacin ≥4 hours before or ≥8 hours after antacids, iron, zinc) 2
5. Monitor for efficacy and toxicity: Watch for QT prolongation, tendon rupture, CNS effects, and treatment response 2
6. Consider therapeutic drug monitoring if clinical response is suboptimal or toxicity is suspected 1